A series of novel 4-chloro-N-(4,5-dihydro-5-oxo-1-R 2 -1H-1,2,4-triazol-3-yl)-5-methyl-2-(R 1 -methylthio)benzenesulfonamide derivatives have been synthesized as potential anticancer agents. The in vitro antitumor activity of some compounds was evaluated in the US National Cancer Institute (NCI) against the NCI-60 cell line panel. The most prominent compound showed remarkable activity against 13 human tumor cell lines representing lung, colon, CNS, melanoma, ovarian, renal, prostate, and breast at low micromolar GI 50 level in the range of 1.9-3.0 lM.
Introduction
The aryl-and heteroarylsulfonamides are widely described compounds revealing a broad spectrum of applications in biological and pharmacological areas [1] . For many years, 2-mercaptobenzenesulfonamide derivatives (MBSAs) have been of interest because of the various biological properties including antitumor [2] [3] [4] [5] [6] [7] [8] [9] [10] , antimicrobial [11, 12] , and antiviral activities [13, 14] , and inhibition of carbonic anhydrase [15] [16] [17] .
It has been known that aryl/heteroarylsulfonamides may act as antitumor agents through a variety of mechanisms such as cell cycle perturbation in the G1 phase, disruption of microtubules, angiogenesis inhibition, and functional suppression of the transcriptional activator NF-Y. The most prominent mechanism was the inhibition of carbonic anhydrase isozymes [18] [19] [20] [21] [22] . Recently, a host of structurally novel arylsulfonamide derivatives have been reported to show substantial anticancer activities in vitro and/or in vivo [23] [24] [25] [26] . We have reported the synthesis and anticancer activity of 2-mercaptobenzenesulfonamides and subsequently extended our study to analogues with various heterocyclic ring systems attached to the benzenesulfonamide scaffold [4-6, 8, 10, 15] (Fig. 1 structure A [4-6, 8, 15] , B [8] , C [10] ).
In this article we investigated new sulfonamide derivatives containing a triazolone ring in their structure. Triazolones are described in the literature as biologically active compounds, including anti-inflammatories [27] , Nk i antagonists [28] , inhibitors of tumor necrosis factor-a-converting enzyme (TACE) [29] , checkpoint kinase-1 inhibitor [30] , anti-tumor agents [31] [32] [33] [34] , and molecular chaperone Hsp90 inhibitor, which is currently in clinical trials for a number of human cancers [35] . Taking into account the interesting properties of triazolones, we have synthesized novel compounds of general structure D (Fig. 1) .
Results and discussion

Chemistry
The main goal of this study was to synthesize and investigate the anticancer activity of the new 2-(alkylthio)benzenesulfonamides containing diverse substituted 1,2,4-triazol-5-one moieties. Thus, we propose a synthetic route leading to the target 2-(alkylthio)-4-chloro-N-(4,5-dihydro-5-oxo-1-R 2 -1H-1,2,-4-triazol-3-yl)-5-methylbenzenesulfonamides as shown in Scheme 1.
Starting 3-aminobenzodithiazine 1 could be readily converted to the corresponding dipotassium 2 and potassium salts 3 and 4, according to the reported procedure for preparation of N-(phenylsulfonyl)cyanamide potassium salts [36] . Novel potassium salts 5-10 were prepared by the reaction of 2 with the corresponding halomethyl electrophiles such as aryl/cycloalkyl/methyl chlorides in methanol or ethanol. Subsequent reaction of salts 3-10 with either hydrazine monohydrochloride, methylhydrazine, p-toluenesulfonyl hydrazide, or various 4-substituted phenylhydrazine hydrochlorides led to the formation of the desired 3-(R 2 -amino)-1-[4-chloro-5-methyl-2-(R 1 -methylthio)phenylsulfonyl]guanidine derivatives 11-25 as depicted in Scheme 1. It is pertinent to know, however, that aminoguanidine 15 was chosen for the synthesis in two different ways (route A and B in Scheme 1). This was supposed to explain some arising synthetic aspects: whether the usefulness of the potassium salt, i.e., 3 with tosyl hydrazide (route A), is higher than the reaction of aminoguanidine 11 with tosyl chloride (TsCl, route B), and whether the reaction proceeds on the N-terminal nitrogen atom of the sulfonylhydrazide moiety or on the second nitrogen atom neighboring the sulfonyl group. As it turned out, both methods products 15 were identical, with structures (IR, NMR) having a N'-substituted sulfonylhydrazide fragment and obtained in almost equal yields.
Many methods are known for the synthesis of 1,2,4-triazol-5-ones. Triazol-5-ones can be prepared for instance by the reaction of the corresponding nitriles via imidates with semicarbazide [37] , from 4-substituted semicarbazides under alkaline conditions [32] , by heating of N 1 ,N 4 -substituted hydrazinecarboxamides in alkaline media [38] , by cyclization of semicarbazide with an excess of phosgene [39] , from the reaction of N-acylureas with arylhydrazines [40] , N-acylurethanes with phenylhydrazines as an Einhorn-Brunner reaction extension, as well as from C-halobenzylidenephenylhydrazones via nitrilimines with phenyl isocyanates [41, 42] .
In the present study we utilized a new method for the synthesis of 1,2,4-triazol-5-ones in the reaction of the corresponding aminoguanudines 11-25 with an excess of p-toluenesulfonyl isocyanate (TsNCO, Scheme 1). The isocyanates are well known as carbonyl precursors [43] and electrophilic agents whose reactions with hydrazines lead to intramolecular cyclization to five-membered heterocyclic rings [44] or reagents in cycloaddition reactions with various compounds having C=N bonds [45] .
Our experiments demonstrated that the proposed synthetic route was an efficient way to prepare the desired N-(4,5-dihydro-5-oxo-1H-1,2,4-triazol-3-yl)benzenesulfonamides 26-40 when an excess of three molar equivalents of tosyl isocyanate was applied in the reaction with the corresponding aminoguanidines 11-25 in anhydrous tetrahydrofuran (THF) for at least 9 h at reflux. It is noteworthy, however, when 2 equivalents of tosyl isocyanate were used, no cyclization product was observed and a complex mixture of products was formed, even after considerable extending of the reaction time.
The structure of the new compounds was confirmed by elemental analyses (C, H, N) and spectral (NMR, IR, MS) data presented in the experimental section. Moreover, X-ray analysis was undertaken to confirm proposed structures on the representative compound 31, which crystallized as pyridinium salt (further specified as 31Pyr, Figs. 2 and 3 ).
Molecular structure
Details on data collection, structure solution, and refinement are given in Table 1 . Compound 31Pyr crystallizes in the monoclinic space group C2/c with (typical for this symmetry) eight molecules in the unit cell. The molecule, being a secondary benzenesulfonamide, is deprotonated at the N1 atom and in the crystal structure is present in the anionic form (Fig. 2) . The proton is accepted by pyridine so a pyridinium ion acts as a counterion. Additionally the The two ions are linked by a charge-assisted hydrogen bond of the (?)NHÁÁÁN(-) type; pyridinium N(5) is a donor, and sulfonamide N(1) is an acceptor. Bonds N(4)-H(4) interact with carbonyl oxygen atoms O5 from the triazolone moiety of the neighboring molecules forming intermolecular hydrogen bonds NHÁÁÁO. These interactions arranged in pairs can be described by the R 2 2 (8) motifs situated about local inversion centers (see Fig. 3 ). Detailed information on hydrogen bonds is given in Table 2 . Packing of molecules in the solid state is reinforced also by p-p stacking interactions between adjacent aromatic rings C5-C10 whose centers of gravity (Cg or centroids) are distant at 3.8513(10) Å . The geometry of the interaction is more precisely characterized in Table 3 .
Biological assay
Compounds 27, 28, and 30-39 were initially tested at a single dose (10 -5 M) in the full NCI-60 cell panel, and the results are shown in Table 4 . The methodology of the in vitro cancer screen is described at the website http://www.dtp.nci.nih. gov/branches/btb/ivclsp.html.
The relatively highest sensitivity to the compounds described here was found for the cell lines of non-small cell lung cancer NCI-H522 cell line to compounds Table 4 ).
The following conclusions can be drawn from the structure-activity relationship study (Table 4) Symmetry code: (i) -x ? 1/2, -y ? 1/2, -z Table 3 Main p-p stacking interaction geometry in crystal structure of 31Pyr
3.8513(10) 17 15.5 3.7104 (7) Ring (1) Further anticancer evaluation was performed at five-dose assay on the distinctive compound 36. The anticancer activity of the tested compound was reported for each cell line by the parameters GI 50 (molar concentration of the compounds that inhibit 50 % net cell growth), TGI (molar concentration of the compounds leading to total inhibition), and LC 50 (molar concentration of the compounds causing 50 % net cell death). The susceptibility of individual subpanels indicates the following order: prostate, colon, CNS, leukemia, ovarian, nonsmall cell lung, melanoma, renal, and breast cancer ( Table 5 ). As shown in Table 5 , compound 36 exhibited remarkable activity at low GI 50 level \11.2 lM (MID GI 50 = 4.2 lM) over a number of cancer cell lines, acting effectively against 13 human tumor cell lines with GI 50 values in the low micromolar range of 1.9-3.0 lM with selectivity toward melanoma MDA-MB-435 (GI 50 = 1.9 lM, TGI = 5.5) and renal A498 (GI 50 = 1.9 lM, TGI = 10.5) cell lines. It is worth mentioning that lines HL-60(TB), NCI-H522, COLO 205, SF-539, MDA-MB-435, OVCAR-3, A498, RXF 393, DU-145, and MDA-MB-468 were characterized by the A COMPARE [47] analysis at the NCI of compound 36 showed a moderate Pearson's correlation coefficient (PCC = 0.473-0.425) with agents disrupting microtubule formation such as maytansine and rhizoxin [48] .
Conclusion
We have developed a new method for the synthesis of a series of 2-(alkylthio)-4-chloro-N-(4,5-dihydro-5-oxo-1-R 2 -1H-1,2, 4-triazol-3-yl)-5-methylbenzenesulfonamides 26-40. The prominent compound 36 showed high (GI 50 = 1.9-3.0 lM) activity against 13 of the tumor cell lines and reasonable activity at level GI 50 \11.2 lM (MID GI 50 = 4.2 lM) over a number cell lines, suggesting that 36 may be a useful lead compound for the search for more powerful anticancer agents with low toxicity against normal cells.
Experimental
The following instruments and parameters were used: melting points: Boetius apparatus; IR spectra: KBr pellets, 400-4,000 cm -1 , Thermo Mattson Satellite FTIR spectrometer; 1 The results of elemental analyses for C, H, and N were in agreement with the calculated values within ±0.3 % range. Thin-layer chromatography (TLC) was performed on Merck Kieselgel 60F254 plates and visualized with UV. N-(5-Methylphenylsulfonyl)cyanamide potassium salts 3, 4 and aminoguanidines 11-14 and 16 were obtained in accordance with the previously described procedures [2, 36] .
To a suspension of 3.05 g 5-chloro-2-(cyanoaminosulfonyl)-4-methylthiophenolate dipotassium salt (2, 9 mmol) in 9 cm 3 methanol 2.4 cm 3 2-(bromomethyl)-1,3-dioxolane (23 mmol) was added dropwise for 5 min. The reaction mixture was stirred at 65°C for 6.5 h, then 12 h at room temperature. The precipitate was collected by filtration. The filtrate was evaporated to dryness, and the residue was triturated with 90 cm 3 diethyl ether to give a second fraction of precipitate. The product was extracted from the combined fractions of solid with hot ethanol to give 2.99 g (86 %) 5 General procedure for the preparation of N-[4-chloro-5-methyl-2-(R 1 -methylthio)phenylsulfonyl]cyanamide potassium salts 6-10
To a suspension of 3.05 g 5-chloro-2-(cyanoaminosulfonyl)-4-methylthiophenolate dipotassium salt (2, 9 mmol) in methanol or ethanol the appropriate halomethyl electrophile was added. The reaction mixture was stirred at room temperature or at 65°C. The precipitate was collected by filtration. The product was separated from inorganic salts by extraction with 200 cm 3 13 General procedure for the preparation of 1-[4-chloro-5-methyl-2-(R 1 -methylthio)phenylsulfonyl]-3-(R 2 -amino)guanidines 15, 17-25
To a suspension of the appropriate N-(phenylsulfonyl)cyanamide potassium salt (3, 5-10, 3.5 mmol) in dry toluene was added the corresponding phenylhydrazine hydrochloride derivative (3.5 mmol) or p-toluenesulfonyl hydrazide (3.5 mmol) in the presence of p-toluenesulfonic acid monohydrate (PTSA, 3.5 mmol). The reaction mixture was stirred at reflux for 1-8 h, and left overnight at 0°C. The precipitate was filtered off, and dried, then treated with 20 cm 3 of water. After vigorously stirring for 30 min the precipitate was collected by filtration, dried, and crystallized from ethanol (15, 17, 19, (21) (22) (23) 25) , ethyl acetate/ hexane (18) , or ethyl acetate (20, 24) . Method B. To a cooled mixture of 1.35 g 11 (3.5 mmol) in 5 cm 3 dry pyridine was added 0.67 g tosyl chloride (3.5 mmol). The ice bath was removed and the mixture was stirred at room temperature for 4 h, then at 60-65°C for 5 h. After standing overnight, the mixture was added dropwise to 12 cm 3 slush and vigorously stirred for 2 h. The solid was filtered off, washed with water (5 9 20 cm 3 ), 1 % HCl (2 9 20 cm 3 ), water (2 9 20 cm 3 ) and dried. Purification from MeOH yielded 15 (86 %); m.p. 242-244°C (dec.); IR and 1 H NMR spectra were identical with an authentic sample of 15. .08 (s, 1H, NHSO 2 ) ppm; 13 13 13 General procedure for the preparation of 4-chloro-5methyl-2-(R 1 -methylthio)-N-(1-R 2 -4,5-dihydro-5-oxo-1H-1,2,4-triazol-3-yl)benzenesulfonamide derivatives [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] The reaction was carried out in a two-neck round-bottom flask (capacity 5 cm 3 ) with drying tube protection. To the cooled (0°C) mixture of the corresponding aminoguanidines 11-25 (1 mmol) in dry THF, 0.46 cm 3 TsNCO (3 mmol) was added dropwise, and the reaction mixture was stirred at room temperature for 1 h, then at reflux for 8-36 h. After cooling (0°C, overnight) the reaction product was isolated in precipitate state (27) (28) (29) (30) (31) (34) (35) (36) (37) (38) (39) (40) or in oil form (26, 32, and 33) and purified by crystallization from ethanol (26) (27) (28) (29) (30) (31) (33) (34) (35) (36) (37) (38) (39) , ethyl acetate (32), or acetonitrile (40). 
